Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lixte Biotechnology Holdings ( (LIXT) ) has provided an update.
On August 18, 2025, Lixte Biotechnology Holdings announced significant corporate developments, including raising $6.5 million through two financings, regaining Nasdaq compliance, and appointing new management and board members. The company also highlighted the validation of its LB-100 compound in a study published in Nature, supporting ongoing clinical trials for ovarian and colorectal cancer, and initiated a new pre-clinical study with the Netherlands Cancer Institute.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies. The company is pioneering a new field of cancer biology called activation lethality, with its lead compound LB-100, a PP2A inhibitor, which has shown promise in enhancing chemotherapy and immunotherapy.
Average Trading Volume: 2,105,076
Technical Sentiment Signal: Hold
Current Market Cap: $16.38M
For a thorough assessment of LIXT stock, go to TipRanks’ Stock Analysis page.